Frequency of Obtaining National Cholesterol Education Program Adult Treatment Panel III Goals for All Major Serum Lipoproteins After Initiation of Lipid Altering Therapy † † Conflicts of interest: Drs. Nichols and Brown are employees of Kaiser Permanente Northwest. Drs. Ambegaonkar and Sazonov are employees of Merck & Company, Inc. Drs. Nichols and Brown have received research support from Amgen, Inc., Thousand Oaks, California; Novo Nordisk A/S, Bagsværd, Denmark; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey; Takeda Pharmaceuticals North America, Inc., Deerfield, Illinois; and GlaxoSmithKline, Inc., London, United Kingdom.
Titel:
Frequency of Obtaining National Cholesterol Education Program Adult Treatment Panel III Goals for All Major Serum Lipoproteins After Initiation of Lipid Altering Therapy † † Conflicts of interest: Drs. Nichols and Brown are employees of Kaiser Permanente Northwest. Drs. Ambegaonkar and Sazonov are employees of Merck & Company, Inc. Drs. Nichols and Brown have received research support from Amgen, Inc., Thousand Oaks, California; Novo Nordisk A/S, Bagsværd, Denmark; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey; Takeda Pharmaceuticals North America, Inc., Deerfield, Illinois; and GlaxoSmithKline, Inc., London, United Kingdom.
Auteur:
Nichols, Gregory A. Ambegaonkar, Baishali M. Sazonov, Vasilisa Brown, Jonathan B.